Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

This article provides a critical review of the pharmacology of CBD and the most recent clinical studies that evaluated its efficacy and safety as adjunctive treatment of seizures associated with LGS and DS. PMID: 30938373 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30938373?dopt=Abstract

Source: Drugs of Today - April 4, 2019 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research